CagriSema
Cagrilintide + semaglutide combination. REDEFINE 1: 22.7% mean body weight loss at 68 weeks.
Mechanism of Action
Bioregulator compound with targeted biochemical activity.
Evidence Chain
CagriSema
COMPOUND
1 Research Goal
• Weight Management
Evidence Strength
3 articles sourced
Knowledge Graph
(4 connections)Research Evidence
(3)Survodutide (BI 456906): Dual GLP-1/Glucagon Receptor Agonist — Clinical Evidence in Obesity and MASH
Survodutide is a dual GLP-1 and glucagon receptor agonist in clinical development by Boehringer Ingelheim for obesity and metabolic dysfunction-associated steatohepatitis (MASH). This review summarizes the clinical evidence.
CagriSema (Cagrilintide + Semaglutide) Combination Therapy: Clinical Evidence from the REDEFINE Trial Program
CagriSema combines cagrilintide (a long-acting amylin analogue) with semaglutide (a GLP-1 receptor agonist) for the treatment of obesity. The REDEFINE clinical development program evaluates the additive weight-loss effects of co-administering amylin and incretin pathway agonism.
Peptide Synergy: Metabolic System Stacking
A systematic review of metabolic peptide synergy, examining how dual and triple receptor agonists interact within the incretin pathway.
Overview
CagriSema is a fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist), developed by Novo Nordisk. This combination represents a novel approach to metabolic therapy by targeting both amylin and GLP-1 pathways simultaneously. The REDEFINE clinical trial program has generated significant interest due to the potential for weight loss results exceeding those of any currently approved monotherapy.
Mechanism of Action
CagriSema combines two complementary mechanisms. Cagrilintide, a long-acting amylin analog, acts on amylin receptors in the brain to promote satiety, slow gastric emptying, and reduce glucagon secretion. Semaglutide, a GLP-1 receptor agonist, promotes insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite through central nervous system effects. The combination of amylin and GLP-1 pathways produces complementary effects on appetite regulation, gastric emptying, and glucose homeostasis, potentially achieving greater weight loss than either component alone.
Research Highlights
The REDEFINE 1 Phase 3 trial demonstrated mean body weight loss of 22.7% at 68 weeks with CagriSema, approaching results previously seen only with bariatric surgery. This exceeded the weight loss achieved by semaglutide alone in comparable studies. Research showed significant improvements in glycemic control, blood pressure, and lipid profiles. The combination approach demonstrated that targeting multiple satiety and metabolic pathways simultaneously can produce additive or synergistic effects on weight loss and metabolic health.
Dosage & Administration
In clinical trials, CagriSema is administered via subcutaneous injection once weekly, with dose escalation to minimize gastrointestinal side effects. For research use only (RUO) — not yet FDA-approved.
Safety Profile
Reported side effects are consistent with the GLP-1 and amylin agonist classes, including nausea, vomiting, diarrhea, and constipation. The combination may produce a higher rate of gastrointestinal side effects than either component alone, though titration mitigates this. Long-term safety data is being collected in ongoing Phase 3 trials. Not yet approved by the FDA for any indication.
References
Novo Nordisk REDEFINE 1 Phase 3 trial results. Novo Nordisk clinical trial data (NCT05669599). All content is for educational and research purposes only.
Related Compounds
Synergy & Compatibility
(5)Computational assessment of bio-regulatory compatibility with compounds sharing research goals. Scores reflect half-life alignment, receptor target overlap, and bioavailability data.
Highest Compatibility
CagriSema + Survodutide
High Compatibility
Shared targets: glp-1 receptor
Computational assessment based on available pharmacology data. Does not account for individual variability, dose-dependent effects, or unstudied interactions. For research use only.
Community Observations
(0)Qualitative, self-reported researcher observations. Distinct from peer-reviewed evidence — not medical advice.
No approved observations yet. Sign in to contribute.
For research use only. Not medical advice.